New insider activity at Merck & Company ( (MRK) ) has taken place on February 14, 2025.
EVP and Chief Information & Digital Officer, David Michael Williams, recently executed a transaction involving the sale of 6,000 shares of Merck & Company stock, generating proceeds amounting to $512,040.
Recent Updates on MRK stock
Merck & Company’s stock has experienced significant bearish activity with a high volume of puts traded, indicating potential investor concern. Recent developments have led to several analysts adjusting their price targets for Merck. Guggenheim lowered its target based on reduced sales estimates for Gardasil, offset by expectations of Keytruda conversion success. TD Cowen downgraded the stock due to challenges with Gardasil in China and concerns over Keytruda’s future exclusivity loss. BofA also lowered its target, citing light 2025 guidance and Gardasil-related issues, while expressing concerns about Keytruda’s valuation. These adjustments reflect the broader market uncertainty and strategic challenges faced by Merck.
More about Merck & Company
YTD Price Performance: -13.61%
Average Trading Volume: 13,305,887
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $216.7B